Literature DB >> 23097579

A candidate molecular biomarker panel for the detection of bladder cancer.

Virginia Urquidi1, Steve Goodison, Yunpeng Cai, Yijun Sun, Charles J Rosser.   

Abstract

BACKGROUND: Bladder cancer is among the five most common malignancies worldwide, and due to high rates of recurrence, one of the most prevalent. Improvements in noninvasive urine-based assays to detect bladder cancer would benefit both patients and health care systems. In this study, the goal was to identify urothelial cell transcriptomic signatures associated with bladder cancer.
METHODS: Gene expression profiling (Affymetrix U133 Plus 2.0 arrays) was applied to exfoliated urothelia obtained from a cohort of 92 subjects with known bladder disease status. Computational analyses identified candidate biomarkers of bladder cancer and an optimal predictive model was derived. Selected targets from the profiling analyses were monitored in an independent cohort of 81 subjects using quantitative real-time PCR (RT-PCR).
RESULTS: Transcriptome profiling data analysis identified 52 genes associated with bladder cancer (P ≤ 0.001) and gene models that optimally predicted class label were derived. RT-PCR analysis of 48 selected targets in an independent cohort identified a 14-gene diagnostic signature that predicted the presence of bladder cancer with high accuracy.
CONCLUSIONS: Exfoliated urothelia sampling provides a robust analyte for the evaluation of patients with suspected bladder cancer. The refinement and validation of the multigene urothelial cell signatures identified in this preliminary study may lead to accurate, noninvasive assays for the detection of bladder cancer. IMPACT: The development of an accurate, noninvasive bladder cancer detection assay would benefit both the patient and health care systems through better detection, monitoring, and control of disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23097579      PMCID: PMC3537330          DOI: 10.1158/1055-9965.EPI-12-0428

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  27 in total

Review 1.  Quantitative analysis of miRNA expression in epithelial cells and tissues.

Authors:  Markus Bitzer; Wenjun Ju; Xiaohong Jing; Jiri Zavadil
Journal:  Methods Mol Biol       Date:  2012

2.  Use of the NMP22 BladderChek test in the diagnosis and follow-up of urothelial cancer: a cross-sectional study.

Authors:  Eu Chang Hwang; Hyang Sik Choi; Seung Il Jung; Dong Deuk Kwon; Kwangsung Park; Soo Bang Ryu
Journal:  Urology       Date:  2010-08-24       Impact factor: 2.649

3.  Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers.

Authors:  Vinata B Lokeshwar; Tomonori Habuchi; H Barton Grossman; William M Murphy; Stefan H Hautmann; George P Hemstreet; Aldo V Bono; Robert H Getzenberg; Peter Goebell; Bernd J Schmitz-Dräger; Jack A Schalken; Yves Fradet; Michael Marberger; Edward Messing; Michael J Droller
Journal:  Urology       Date:  2005-12       Impact factor: 2.649

4.  Performance of different small sample RNA amplification techniques for hybridization on Affymetrix GeneChips.

Authors:  Florian Wagner; Uwe Radelof
Journal:  J Biotechnol       Date:  2007-02-25       Impact factor: 3.307

5.  DNA microarray expression profiling of bladder cancer allows identification of noninvasive diagnostic markers.

Authors:  Lourdes Mengual; Moisès Burset; Elisabet Ars; Juan José Lozano; Humberto Villavicencio; María José Ribal; Antonio Alcaraz
Journal:  J Urol       Date:  2009-06-18       Impact factor: 7.450

6.  Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative.

Authors:  Patrick M Bossuyt; Johannes B Reitsma; David E Bruns; Constantine A Gatsonis; Paul P Glasziou; Les M Irwig; Jeroen G Lijmer; David Moher; Drummond Rennie; Henrica C W de Vet
Journal:  Fam Pract       Date:  2004-02       Impact factor: 2.267

7.  Commentary: the role of cytologic analysis of voided urine in the work-up of asymptomatic microhematuria.

Authors:  Deep Trivedi; Edward M Messing
Journal:  BMC Urol       Date:  2009-09-10       Impact factor: 2.264

Review 8.  Bladder cancer.

Authors:  Donald S Kaufman; William U Shipley; Adam S Feldman
Journal:  Lancet       Date:  2009-06-10       Impact factor: 79.321

9.  Urine-based assays for the detection of bladder cancer.

Authors:  Patrick Villicana; Bryant Whiting; Steve Goodison; Charles J Rosser
Journal:  Biomark Med       Date:  2009-06-01       Impact factor: 2.851

10.  Utility of serial urinary cytology in the initial evaluation of the patient with microscopic hematuria.

Authors:  Kogenta Nakamura; Ali Kasraeian; Kenneth A Iczkowski; Myron Chang; John Pendleton; Satoshi Anai; Charles J Rosser
Journal:  BMC Urol       Date:  2009-09-10       Impact factor: 2.264

View more
  45 in total

1.  The Influence of Race on Overall Survival in Patients with Newly Diagnosed Bladder Cancer.

Authors:  Casey DeDeugd; Makito Miyake; Diego Aguilar Palacios; Charles J Rosser
Journal:  J Racial Ethn Health Disparities       Date:  2014-09-11

Review 2.  Developing proteomic biomarkers for bladder cancer: towards clinical application.

Authors:  Maria Frantzi; Agnieszka Latosinska; Leif Flühe; Marie C Hupe; Elena Critselis; Mario W Kramer; Axel S Merseburger; Harald Mischak; Antonia Vlahou
Journal:  Nat Rev Urol       Date:  2015-05-26       Impact factor: 14.432

3.  Angiogenin promotes tumoral growth and angiogenesis by regulating matrix metallopeptidase-2 expression via the ERK1/2 pathway.

Authors:  M Miyake; S Goodison; A Lawton; E Gomes-Giacoia; C J Rosser
Journal:  Oncogene       Date:  2014-02-24       Impact factor: 9.867

4.  Knockdown of TMEM45A inhibits the proliferation, migration and invasion of glioma cells.

Authors:  Wei Sun; Guanzhong Qiu; Yongxiang Zou; Zheng Cai; Peng Wang; Xianbin Lin; Jinxiang Huang; Lei Jiang; Xuehua Ding; Guohan Hu
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

5.  External validation of a multiplex urinary protein panel for the detection of bladder cancer in a multicenter cohort.

Authors:  Li-Mei Chen; Myron Chang; Yunfeng Dai; Karl X Chai; Lars Dyrskjøt; Marta Sanchez-Carbayo; Tibor Szarvas; Ellen C Zwarthoff; Vinata Lokeshwar; Carmen Jeronimo; Alexander S Parker; Shanti Ross; Michael Borre; Torben F Orntoft; Tobias Jaeger; Willemien Beukers; Luis E Lopez; Rui Henrique; Paul R Young; Virginia Urquidi; Steve Goodison; Charles J Rosser
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-06-11       Impact factor: 4.254

Review 6.  Analysis of the transcriptome in molecular epidemiology studies.

Authors:  Cliona M McHale; Luoping Zhang; Reuben Thomas; Martyn T Smith
Journal:  Environ Mol Mutagen       Date:  2013-08-01       Impact factor: 3.216

7.  Urinary protein biomarker panel for the detection of recurrent bladder cancer.

Authors:  Charles J Rosser; Myron Chang; Yunfeng Dai; Shanti Ross; Lourdes Mengual; Antonio Alcaraz; Steve Goodison
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-04-08       Impact factor: 4.254

8.  Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model.

Authors:  Evan Gomes-Giacoia; Makito Miyake; Steve Goodison; Charles J Rosser
Journal:  Mol Cancer Ther       Date:  2013-09-26       Impact factor: 6.261

9.  PAI-1 leads to G1-phase cell-cycle progression through cyclin D3/cdk4/6 upregulation.

Authors:  Evan Gomes Giacoia; Makito Miyake; Adrienne Lawton; Steve Goodison; Charles J Rosser
Journal:  Mol Cancer Res       Date:  2014-01-24       Impact factor: 5.852

10.  Multiplex protein signature for the detection of bladder cancer in voided urine samples.

Authors:  Charles J Rosser; Shanti Ross; Myron Chang; Yunfeng Dai; Lourdes Mengual; Ge Zhang; Jeongsoon Kim; Virginia Urquidi; Antonio Alcaraz; Steve Goodison
Journal:  J Urol       Date:  2013-06-11       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.